OpenEvidence Funding Doubt Exposes $20B AI Dilemma
OpenEvidence may skip a $200M raise at a $20B valuation as fast growth and breakeven cash flow make dilution hard to justify.
Jul 20, 20265 min read0 reactions0 comments
Tag archive
OpenEvidence may skip a $200M raise at a $20B valuation as fast growth and breakeven cash flow make dilution hard to justify.